Nabızca
Remote patient monitoring for chronic diseases.
Nabızca is a digital health startup that monitors blood pressure, blood sugar and oxygen levels of patients with chronic conditions through wearable devices and a mobile app. It sends risk alerts to doctors; in a pilot at three private hospitals it reduced emergency visits by 31 percent.
Investment facts
- Sector: Digital health
- Sarmal's first investment: 2022, at Seed stage, USD 900K
- Fund: Fund II
- Founders: Dr. Gizem Aral, Onur Balkan
- Headquarters: Ankara
- Employees: 28
- Status: Active portfolio
For collaboration or corporate pilot requests regarding this company, you can contact the Sarmal Ventures platform team.
Why we invested
Managing chronic diseases is the largest item in healthcare spending. We were impressed by Nabızca's clinically validated approach integrated into the physician workflow. The company completed its medical device registration in 2025 and signed reimbursement agreements with two insurers.
Sarmal Ventures handles press and collaboration requests about portfolio companies through its platform team; the company's latest metrics are published in the annual report.
